Biotricity (BTCY) investor relations material

Business overview and market opportunity

• Focuses on smart cardiac monitoring, addressing chronic cardiac conditions and long wait times for cardiology care.

• Core product is a cellular-enabled, algorithm-driven device for real-time cardiac data analysis and emergency response.

• Achieved profitability as of March, with trailing 12-month revenue at $16M and forward-looking at $18M; margins stable at 82-83%.

• Retention rate is 92%, indicating strong customer loyalty and recurring revenue.

• Achieved economies of scale, maintaining full R&D and commercial teams while scaling profitably.

Product features and technology

• Device integrates cellular connectivity, automatically switching between major telecom providers to avoid outages.

• Provides physicians with real-time data and comprehensive reports for faster, more accurate decision-making.

• Solution is insurance reimbursable, enabling physicians to bill $500 per patient versus $25 with traditional methods.

• Subscription model generates $250 per device monthly, with devices lasting two years and supporting multiple patients.

• Vertically integrated technology company with expertise in both hardware and software, led by a team with tech industry backgrounds.

Growth strategy and future plans

• Expanding into disease management and implantable device management, aiming for each division to match current ambulatory revenue over time.

• Disease management and implantable programs piloted, with $1M expected in disease management revenue this year.

• Companion app launched to drive patient engagement, with 70,000 downloads and positive feedback supporting disease management adoption.

• Partnerships with ResMed and major GPOs (HealthTrust, Vizient, Premier) facilitate market access and growth.

• Plans to expand commercial team to increase market penetration, especially in the 35 states covering 90% of the target market.